Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
For the six months, sales was USD 0.118129 million compared to USD 0.118129 million a year ago. Revenue was USD 0.118129 million compared to USD 0.118129 million a year ago. Net loss was USD 0.472233 million compared to net income of USD 1.58 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to basic earnings per share from continuing operations of USD 0.41 a year ago.